Alzheimer’s Disease: Treatment Strategies and Their Limitations

Abstract

Alzheimer’s disease (AD) is the most frequent case of neurodegenerative disease and is becoming a major public health problem all over the world. Many therapeutic strategies have been explored for several decades; however, there is still no curative treatment, and the priority remains prevention. In this review, we present an update on the clinical and physiological phase of the AD spectrum, modifiable and non-modifiable risk factors for AD treatment with a focus on prevention strategies, then research models used in AD, followed by a discussion of treatment limitations. The prevention methods can significantly slow AD evolution and are currently the best strategy possible before the advanced stages of the disease. Indeed, current drug treatments have only symptomatic effects, and disease-modifying treatments are not yet available. Drug delivery to the central nervous system remains a complex process and represents a challenge for developing therapeutic and preventive strategies. Studies are underway to test new techniques to facilitate the bioavailability of molecules to the brain. After a deep study of the literature, we find the use of soft nanoparticles, in particular nanoliposomes and exosomes, as an innovative approach for preventive and therapeutic strategies in reducing the risk of AD and solving problems of brain bioavailability. Studies show the promising role of nanoliposomes and exosomes as smart drug delivery systems able to penetrate the blood–brain barrier and target brain tissues. Finally, the different drug administration techniques for neurological disorders are discussed. One of the promising therapeutic methods is the intranasal administration strategy which should be used for preclinical and clinical studies of neurodegenerative diseases.

Butyrylcholinesterase-Activated Near-Infrared Fluorogenic Probe for In Vivo Theranostics of Alzheimer’s Disease

“…The filtrate was then concentrated and diluted with petroleum ether to give intermediate 5 as a pink solid (3.9 g, yield 56%). 1 (6). Intermediate 3 (2 g, 5.90 mmol) and intermediate 5 (0.51 g, 2.95 mmol) was dissolved in acetic anhydride, followed by the addition of sodium acetate (1.9 g, 23.2 mmol).…”

Gout/hyperuricemia reduces the risk of Alzheimer's disease: A meta‐analysis based on latest evidence

“…Alzheimer's disease (AD) is a complex, irreversible and progressive neurodegenerative disorder of the brain, which is the most frequent form of dementia, a general term for persistent memory decline, learning and other cognitive dysfunction that interfere with daily life (Alzheimer's Disease Facts & Figures, 2021). However, there is no valid treatment for AD (Passeri et al., 2022). Therefore, it is essential to investigate the pathogenesis and potential risk factors of AD to improve the prevention and treatment of its onset and progression.…”

miRNA‐137‐5p improves spatial memory and cognition in Alzheimer's mice by targeting ubiquitin‐specific peptidase 30

“…Alzheimer's disease (AD) is a degenerative brain condition characterized by the progressive deterioration of cognitive function and memory loss 1–3 . The severity of dementia in AD patients can range from mild to severe, leading to complete dependence on others for daily activities.…”